ESC Congress 2022, the annual meeting of the European Society of Cardiology, was jam-packed with eye-opening new research from many of the leading voices in cardiovascular and vascular medicine. These six sessions were just some of the weekend's many highlights. 

The promising results were presented at ESC Congress 2022 and published in the New England Journal of Medicine. Medtronic's new-look device is not yet approved for sale or distribution. 

A two-medication strategy after CABG surgery reduces the risk that grafts will fail, but it also increases the risk of serious bleeding. As one surgeon said, "the benefit comes at a price.”

A care team with the Sanger Heart & Vascular Institute has shared details about its recent successes in TMVR and TAVR. Cardiologist Michael Rinaldi, MD, highlighted the importance of having "a coordinated team of specialists with expertise in treating valve diseases."

The new findings, presented during ESC Congress 2022 and published in the New England Journal of Medicine, suggest that prescribing these new-look pills to heart patients could boost outcomes while also improving medication adherence.

Elderly patients are often not eligible for oral anticoagulant therapy due to the risk of bleeding events or other adverse outcomes. A very low dose of edoxaban, however, appears to be a safe treatment option, even for especially frail patients.

Following medical discharge, a program consisting of at-home visits, telehealth appointments and clinic visits resulted in better outcomes and lower healthcare costs than typical post-discharge care.

A team of Cleveland Clinic researchers tracked data from nearly 23,000 patients, sharing their findings in the American Journal of Cardiology. 

Alma, a membership-based network focused on mental healthcare, has raised $130 million in a Series D funding round. The network nabbed investments from some big names, including Cigna Ventures.